Search
for

    Sort by

    Community Join

    210-240 / 435 results

      community First 3 pics are at 6 months .5 mg fin daily, last 3 are 13 months

      in Progress Pictures  75 upvotes 1 year ago
      The user experienced improved hair at 6 months using 0.5 mg finasteride daily but noticed more scalp visibility and potential hair loss at 13 months, questioning if this was due to shedding or the treatment not working. Some respondents suggested the possibility of a shed or scalp inflammation, while others observed improvements or advised checking for underlying scalp conditions.

      community If RU58841 is such an effective anti androgen

      in Research/Science  46 upvotes 1 year ago
      RU58841 is discussed as a topical anti-androgen for hair loss, but its effectiveness and safety are not well-documented, leading to mixed opinions and experiences among users. Some combine it with finasteride, but concerns about side effects and lack of FDA approval limit its popularity.

      community Starting Pyrilutimide 5% Update

      in Treatment  1 upvotes 1 year ago
      The user started using Pyrilutamide 5% for hair loss and has not experienced side effects after two days. They previously had side effects from Fluridil and topical Minoxidil 5%, and their hair continued thinning with topical Spironolactone.

      community Tressless When They See Verteporfin Results

      in Transplants  182 upvotes 1 year ago
      The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.

      community Whats the safety Profile for Breezula?

      in Treatment  7 upvotes 3 years ago
      The conversation is about the safety of Breezula compared to RU58841 for hair loss treatment. The user believes Breezula is safer but less effective than RU58841.

      community The Cure isn't 5 years away; it's already here.

      in Research/Science  982 upvotes 1 week ago
      PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.

      community Likelihood of a new treatment?

      in Chat  6 upvotes 1 month ago
      New hair loss treatments like stem cells, hair cloning, and gt20029 are unlikely to be available in the next 5-10 years, with some trials possibly starting by 2026. Current treatments like Minoxidil and Finasteride have been used for decades, and new developments depend on funding and successful trials.

      community When is GT20029 going to come out?

      in Research/Science  38 upvotes 3 months ago
      The conversation discusses the anticipation and skepticism around the release of GT20029 for hair loss treatment. The original poster has been using Finasteride and Minoxidil but is hopeful for GT20029, while others express doubts about its timely release and suggest alternatives like KX826 and hair transplants.

      community Anyone still waiting on Pryiltamide order

      in Chat  2 upvotes 4 months ago
      The user is frustrated with the delayed delivery of their Pryiltamide order from Koshine. They mention the order was shipped on August 23 but have received no updates since.

      community blueprint is working so well it seems

      in Chat  535 upvotes 5 months ago
      The conversation discusses a person successfully using a combination of Minoxidil, finasteride, and other treatments for hair loss, resulting in significantly improved hair. Despite some criticism, many admire his dedication to health and anti-aging research.

      community Breaking hair loss news! GT20029 is a resounding success!

      in Product  132 upvotes 8 months ago
      GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  134 upvotes 8 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community How to use redensyl hair serum?

      in Product  3 upvotes 9 months ago
      The conversation is about the correct usage of a hair serum containing redensyl, procapil, capixil, and baicapil. The user is seeking advice on the amount to apply and whether washing hair after application is necessary.

      community Where is GT20029 already? Grrrr

      in Research/Science  19 upvotes 10 months ago
      The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

      community 4 month progress (23M) on the Big 3. [NW7 when I started, I think]

      in Progress Pictures  164 upvotes 11 months ago
      A 23-year-old man shared his 4-month hair regrowth progress using 1mg oral finasteride daily, 5% minoxidil with finasteride topical twice a day, multivitamins, microneedling, head massages, and ketoconazole shampoo. He's unsure of his current Norwood scale classification and is asking for help to determine it, with suggestions ranging from NW4 to NW4.5.

      community GT20029 phase II results release date?

      in Research/Science  17 upvotes 11 months ago
      The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.